In another example of price gouging for cancer drugs, Celgene Corp. said it will sell Revlimid for $6,195 a month, (more than $74,000 a year) for patients with multiple myeloma.
The FDA approved the drug this week for use in combination with dexamethasone in patients with multiple myeloma, a cancer of the bone marrow. The drug was already on the market for a rare blood disorder called myelodysplastic syndrome at a monthly price of $4,600, or about $55,000 if used for a year.
The recommended dose for multiple myeloma is 25 milligrams, 2 1/2 times the 10-milligram capsule typically prescribed for patients with the blood disorder. The price for the 25-milligram version, which the company announced in a conference call Friday, is about 30% higher than the 10-milligram dose.
A Morgan Stanley analyst estimates Celgene stands to make a 97% gross margin (the profit excluding marketing and corporate costs) on Revlimid.
Source: Dow Jones
3 comments:
And what did it cost to develop?
Dont give me that "development cost" rubbish!
Remember, I am an Insider!
The games the accountants play are all known to me.....
P.S. I like your blog and have linked to it.
Post a Comment